Printer Friendly

AVI BioPharma Receives Notice of Allowance for a Patent Application Covering the Use of NeuGene Antisense Technology for the Development of a New Class of Antibiotics.

PORTLAND, Ore. -- AVI BioPharma, Inc. (Nasdaq:AVII), today announced that it has received a Notice of Allowance for U.S. Patent No. 7,049,431 titled "Antisense Antibacterial Cell Division Composition and Method." The patent describes the use of NEUGENE (R) antisense compounds to target bacterial cell division and cell cycle genes for the development of a new class of antibiotics. This is the central patent covering AVI's antibiotic development program referred to as NeuBiotics.

The patent allowance follows a related publication in the Journal of Antimicrobial Chemotherapy, volume 55/2005, pages 983-988, in which an 11-base NEUGENE compound targeting the acpP gene of E. coli significantly inhibited bacterial growth in both pure culture and in infected mice. These studies showed, for the first time, that an antisense DNA analog can inhibit bacterial growth in animal infections. The relatively short oligomer lengths should offer an improved safety index as they are expected to have no effect on human gene expression.

"This antisense approach to the development of a new class of antibiotics has broad potential to treat infections caused by emerging strains of antibiotic-resistant gram-positive bacteria," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. "We believe we can continue to explore the use of NEUGENE antibiotics to include a variety of gene targets, newly emerging infectious disease, and enhance the potency and efficacy in additional animal infection studies."

NeuBiotics are NeuGene antisense compounds containing just 10 to 13 subunits that target prokaryotic (bacteria) genes rather than the typical 18 to 24 subunits used to target higher organisms including man. The shorter antisense polymers are able to gain entry into the more complex bacterial cell wall and inactivate the targeted gene but are too short to inhibit mammalian genes.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:May 24, 2006
Previous Article:Occam Networks Elects Brian Strom, Former SureWest Communications' President and CEO, to Board of Directors; Former USTA Chairman Strom Adds Proven...
Next Article:Xethanol to Acquire Plant in Georgia; Proposed Purchase of Pfizer Manufacturing Complex Through CoastalXethanol Subsidiary.

Related Articles
AVI BioPharma Announces Presentation of Data at Transcatheter Cardiovascular Therapeutics Conference.
AVI BioPharma to Present at Rodman & Renshaw 3rd Annual Security, Biodefense & Connectivity Investor Conference.
AVI BioPharma Provides Cardiovascular Program Update; Notice of Allowance of Two Patents Strengthens Cardiovascular Restenosis Program.
AVI BioPharma Announces Publication of Positive Results from New Class of Antibiotics Using NEUGENE Antisense Technology.
AVI BioPharma Announces Positive Clinical Trial Results Delivering NEUGENE Antisense Drugs to the Central Nervous System.
AVI BioPharma Awarded $28 Million Biodefense Research Contract by Department of Defense/DTRA.
AVI BioPharma and Eleos Announce Cross-License Agreement for p53 Therapeutics.
AVI BioPharma Completes Purchase of Building for GMP Manufacturing.
AVI BioPharma Reports Positive Pre-Clinical Influenza Data.
AVI BioPharma Receives DoD Contracts for Bioterrorism Response Therapies.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters